Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Alzheimer drug gets accelerated approval on 27% improvement

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jan 09, 2023 1:47pm

139 Views

Post# 35211584

RE:Alzheimer drug gets accelerated approval on 27% improvement

Another example has Zymeworks moving towards gaining an accelerated approval in biliary tract cancer for its HER2 bispecific antibody which demonstrated an ORR of 41.3%, one complete response and 18 partial responses in 21 evaluable patients on zanidatamab, showing a 90.5% response rate, a six-month PFS of over 95%, and a median response of 12.9 months in patients enrolled in a Phase IIb pivotal trial.

https://endpts.com/zymeworks-shows-positive-yet-early-pivotal-data-in-bile-duct-cancers-plans-accelerated-approval-run/

<< Previous

Bullboard Posts

Next >>

The long-term forecast for lithium stocks in 2024